STOCK TITAN

Sagimet Biosciences (SGMT) DEF 14A Filings

SGMT NASDAQ

Here are the DEF 14A proxy statements from Sagimet Biosciences Inc. (SGMT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SGMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGMT filings page.

Rhea-AI Summary

Sagimet Biosciences Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 12, 2026 at 9:30 a.m. Pacific Time. Stockholders of record as of April 17, 2026, holding 32,017,613 shares of Series A common stock, may vote online, by phone, mail or during the meeting.

Investors will elect four Class III directors—Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D.—to three-year terms ending in 2029, and ratify KPMG LLP as independent auditor for 2026. The eight-member Board includes six independent directors and uses annual self-evaluations, fully independent committees and a lead independent director structure.

The company highlights recent progress, including China partner Ascletis’ positive Phase 3 acne results and NMPA acceptance of a denifanstat NDA, initiation of a Phase 1 trial for TVB‑3567, and establishment of a $75.0 million at-the-market program for Series A common stock.